HCC1187 Xenograft Model Service for Breast Cancer

The HCC1187 xenograft model is a critical in vivo tool for studying the aggressive characteristics of Triple-Negative Breast Cancer (TNBC) and evaluating the efficacy of novel targeted therapies. Alfa Cytology offers specialized HCC1187 xenograft model services, providing a robust preclinical platform supported by our extensive expertise in mammary oncology and specialized model construction.

Overview of HCC1187 Xenograft Model for Breast Cancer

The HCC1187 cell line is a well-established model for Triple-Negative Breast Cancer (TNBC), specifically representing the basal-like molecular subtype. Originally isolated from a primary ductal carcinoma, this model is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 amplification. HCC1187 is particularly valuable for researchers investigating DNA repair deficiencies and poly (ADP-ribose) polymerase (PARP) inhibitor sensitivity, as it carries a distinct genetic profile that mimics the clinical challenges of refractory breast cancer.

When utilized in in vivo studies, HCC1187 xenografts demonstrate rapid and aggressive growth kinetics. This model effectively recapitulates the high proliferative index and genomic instability observed in clinical TNBC patients.

Cell Line Information: HCC1187

The HCC1187 cell line maintains a stable epithelial morphology and preserves its TNBC profile through successive in vitro passages and in vivo cycles.

Alfa Cytology is dedicated to providing high-quality preclinical data through the meticulous management of every in vivo project. Our scientists utilize advanced validation techniques to confirm the phenotypic identity of the HCC1187 model, ensuring that the results you receive are biologically relevant and reproducible.

Our Services

Workflow of HCC1187 Xenograft Model Construction

Alfa Cytology follows a standardized and scientifically rigorous workflow to ensure the successful construction of the HCC1187 xenograft model:

• Cell Culture & QC: HCC1187 cells are expanded in optimized growth media and harvested during the exponential growth phase. We perform rigorous QC, including STR profiling, to ensure cell identity and high viability.
• Host Selection: Healthy immunocompromised mice (such as Nude or SCID strains) are selected and acclimatized to our facility to ensure physiological stability prior to study initiation.
• Standardized Inoculation: A precisely calibrated suspension of HCC1187 cells is prepared. The cells are injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes, often utilizing a biological matrix to enhance initial tumor take.
• Growth Monitoring: Following inoculation, tumor volumes and animal weights are monitored longitudinally using precision digital calipers to establish robust growth curves and ensure animal welfare.
• Randomization: Once the tumors reach a statistically significant volume, mice are randomized into specific treatment and control groups to ensure balanced cohorts for efficacy evaluation.

Fig 1. HCC1187 Xenograft Model Construction Workflow

Case Study - HCC1187 Xenograft Model Development

In a recent study conducted at Alfa Cytology, the HCC1187 xenograft model was utilized to evaluate the therapeutic potential of a novel DNA-damage response inhibitor. Our team achieved highly reproducible tumor engraftment and uniform growth kinetics across all cohorts, allowing for a clear and statistically sound assessment of drug efficacy. The in vivo study successfully demonstrated significant tumor growth inhibition in the treatment group.

Why Choose Alfa Cytology?

• TNBC Specialization: Deep expertise in establishing and characterizing aggressive basal-like breast cancer models.
• Optimized Take Rates: Proprietary inoculation protocols that ensure consistent tumor development.
• High-Fidelity Data: Precise longitudinal monitoring and comprehensive endpoint analysis (IHC, PK/PD).
• Quality Commitment: Strict adherence to international ethical standards and scientific integrity.

Contact Us

Are you ready to advance your TNBC drug discovery program with the HCC1187 xenograft model? The expert team at Alfa Cytology is available to provide the technical precision and tailored study designs your project requires. Please reach out to us today to discuss your experimental goals, or contact us directly to request a project consultation and detailed quote.

For research use only. Not intended for any clinical use.